A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of LYL314, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

16537LYL314-101-NCT05826535OpenA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of LYL314, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin LymphomaLYL314-101NCT05826535IndustrialAdultTreatmentI/IINon-Hodgkin LymphomaRoswarski, JosephGeorgetown University Medical Center : Gayle Cramer; Lombardi Comprehensive Cancer Center : Gayle CramerCell Therapy; LymphomaOncology GroupLombardi Comprehensive Cancer Center (LCCC)6887Gayle CramerGayle Cramer+1 202-687-1116gc604@georgetown.eduClinical Research Nurse 2 2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>